Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Biologic therapy. Chemotherapy. Institut Gustave-Roussy, Villejuif Cedex, France



Survival: 32.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: France
   
City/State/Province: Villejuif Cedex
   
Hospital: Institut Gustave-Roussy
   
Journal: Link
   
Date: 6/2008

Description:
Patients: This phase III study involved 762 women with ovarian or peritoneal cancer. The majority (690) had ovarian cancer. The median age of the patients was 59, ranging from 25 to 86 years of age.

Treatment: These women were treated with the chemotherapy drugs paclitaxel and carboplatin, with or without valspodar (PSC 833).

Toxicity: The most common grade 3 and 4 toxicities were neutropenia and leucopenia. These occurred in over 70% of patients in each treatment group, and were more common in the women treated with paclitaxel, carboplatin, and valspodar (PSC 833) than those treated with paclitaxel and carboplatin. Other grade 3 and 4 toxicities were fatigue, athenia, ataxia, nausea, vomiting, alopecia, and febrile neutropenia.

Results: The median overall survival was 32 months for the group of women treated with paclitaxel, carboplatin, and valspodar (PSC 833), and 28.9 months for those treated with paclitaxel and carboplatin.

Support: This study was supported by Novartis Oncology, which developed valspodar (PDC 833).

Correspondence: Dr. Catherine Lhomme

E-mail to a Friend Email Physician More Information